T1	Participants 123 156	patients with chronic hepatitis C
T2	Participants 340 408	patients with chronic hepatitis C and advanced fibrosis or cirrhosis
T3	Participants 604 623	517 HALT-C patients
T4	Participants 194 268	Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial
#1	AnnotatorNotes T4	Participants were those in this trial.
